Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neuroblastoma 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Fulvestrant 3Alpelisib 3duvelisib 2Cetuximab 2volagidemab 1talazoparib 1ruxolitinib 1parsaclisib 1olaparib 1obinutuzumab 1lorlatinib 1encorafenib 1dapagliflozin 1cobimetinib 1chiauranib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1NVP-BKM120 1Drug Therapy 1CYH33 1Aspirin 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hereditary Sensory and Autonomic Neuropathies × SF 1126 × Clear all
NCT02644122 2018-07-11

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

University of California, San Diego

Phase 2 Terminated
1 enrolled 6 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡